Overview of recent results of proton radiotherapy in the treatment of head and neck tumors

1. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56 (1): 83–88. Doi: 10.1016/s0360-3016 (03) 00073-7.

2. Holliday EB, Kocak-Uzel E, Feng L et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Med Dosim 2016; 41 (3): 189–194. Doi: 10.1016/j.meddos.2016. 01.002.

3. Jain V, Irmen P, O‘Reilly S et al. Predicted secondary malignancies following proton versus photon radiation for oropharyngeal cancers. Int J Part Ther 2020; 6 (4): 1–10. Doi: 10.14338/IJPT-19-00076.1.

4. Nangia S, Gaikwad U, Noufal MP et al. Proton therapy and oral mucositis in oral & oropharyngeal cancers: outcomes, dosimetric and NTCP benefit. Radiat Oncol 2023; 18 (1): 121. Doi: 10.1186/s13014-023-02317-1.

5. Anderson JD, DeWees TA, Ma DJ et al. A Prospective Study of Mucosal Sparing Radiation Therapy in Resected Oropharyngeal Cancer Patients. Int J Radiat Oncol Biol Phys 2023; 115 (1): 192–201. Doi: 10.1016/j.ijrobp.2022.06.057.

6. Walser MA, Bachmann N, Kluckert J et al. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands. Br J Radiol 2023; 96 (1148): 20220672. Doi: 10.1259/bjr.20220672.

7. Cao J, Zhang X, Jiang B et al. Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia. Radiother Oncol 2021; 160: 32–39. Doi: 10.1016/ j.radonc.2021.03.036.

8. Meijer TWH, Scandurra D, Langendijk JA. Reduced radiation-induced toxicity by using proton therapy for the treatment of oropharyngeal cancer. Br J Radiol 2020; 93 (1107): 20190955. Doi: 10.1259/bjr.20190955.

9. Mendenhall WM, Beitler JJ, Saba NF et al. Proton Beam Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma. Int J Part Ther 202; 9 (4): 243–252. Doi: 10.14338/IJPT-22-00030.1.

10. Sethi S, O‘Neil M, Jensen E et al. Toxicity with proton therapy for oral and/or oropharyngeal cancers: A scoping review. J Oral Pathol Med 2023; 52 (7): 567–574. Doi: 10.1111/jop.13426.

11. Grant SR, Hutcheson KA, Ye R et al. Prospective longitudinal patient-reported outcomes of swallowing following intensity modulated proton therapy for oropharyngeal cancer. Radiother Oncol 2020; 148: 133–139. Doi: 10.1016/ j.radonc.2020.04.021.

12. Rwigema JM, Langendijk JA, van der Laan PH et al. A Model-Based Approach to Predict Short-Term Toxicity Benefits With Proton Therapy for Oropharyngeal Cancer. Int J Radiat Oncol Biol Phys 2019; 104 (3): 553–562. Doi: 10.1016/ j.ijrobp.2018.12.055.

13. Wright CM, Baron J, Lee DY et al. Dosimetric Results for Adjuvant Proton Radiation Therapy of HPV-Associated Oropharynx Cancer. Int J Part Ther 2021; 8 (4): 47–54. Doi: 10.14338/IJPT-D-21-00018.

14. Holliday EB, Kocak-Uzel E, Feng L et al. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. Med Dosim 2016; 41 (3): 189–194. Doi: 10.1016/ j.meddos.2016.01.002.

15. Manzar GS, Lester SC, Routman DM et al. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. Radiother Oncol 2020; 147: 64–74. Doi: 10.1016/ j.radonc.2020.03.010.

16. Jain V, Irmen P, O‘Reilly S e tal. Predicted Secondary Malignancies following Proton versus Photon Radiation for Oropharyngeal Cancers. Int J Part Ther 2020; 6 (4): 1–10. Doi: 10.14338/IJPT-19-00076.1.

17. Brodin NP, Kabarriti R, Pankuch M et al. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy. Int J Radiat Oncol Biol Phys 2019; 104 (3): 540–552. Doi: 10.1016/j.ijrobp.2018.11.039.

18. Sio TT, Lin HK, Shi Q et al. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys 2016; 95 (4): 1107–1114. Doi: 10.1016/ j.ijrobp.2016.02.044.

19. Thaker NG, Boyce-Fappiano D, Ning MS et al. Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. Int J Part Ther 2021; 8 (1): 374–382. Doi: 10.14338/IJPT-20-00042.1.

20. Brodin NP, Kabarriti R, Schechter CB et al. Individualized quality of life benefit and cost-effectiveness estimates of proton therapy for patients with oropharyngeal cancer. Radiat Oncol 2021; 16 (1): 19. Doi: 10.1186/s13014-021-01745-1.

21. Smith GL, Fu S, Ning MS et al. Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. Int J Part Ther 2021; 8 (1): 319–327. Doi: 10.14338/IJPT-20-00067.1.

22. Chia-Lun Chang, Kuan-Chou Lin, Wan-Ming Chen et al. Comparing the Oncologic Outco-mes of Proton Therapy and Intensity-Modu- lated Radiation Therapy for Head and Neck Squamous Cell Carcinoma. 2023 [online]. Dostupné na: https: //ssrn.com/abstract=446 5968 or http: //dx.Doi.org/10.2139/ssrn.4465968.

23. Kubeš J, Vondráček V, Andrlík M et al. Proton penci-beam scanning radiotherapy in the treatment of nasopharyngeal cancer: dosimetric parameters and 2-year results. Eur Arch Otorhinolaryngol 2021; 278 (3): 763–769. Doi: 10.1007/s00405-020-06175-5.

24. Fountzilas G, Ciuleanu E, Bobos M et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation. Ann Oncol 2012; 23 (2): 427–435. Doi: 10.1093/annonc/mdr 116.

25. Cao CN, Luo JW, Gao L et al. Concurrent chemotherapy for T4 classification nasopharyngeal carcinoma in the era of intensitymodulated radiotherapy. PLoS ONE 2015; 10 (3): e0119101. Doi: 10.1371/journal.pone.0119101.

26. Lee N, Harris J, Garden AS et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol 2009; 27 (22): 3684–3690. Doi: 10.1200/JCO.2008.19.9109.

27. Songthong AP, Kannarunimit D, Chakkabat C et al. A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events. Radiat Oncol 2015; 10: 166. Doi: 10.1186/s13014-015-0472-y.

28. Levin WP, Kooy H, Loeffler JS et al. Proton beam therapy. Br J Cancer 2005; 93 (8): 849–854. Doi: 10.1038/sj.bjc.6602754.

28. Ou X, Zhou X, Shi Q et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Oncotarget 2015; 6 (35) : 38381–38397. Doi: 10.18632/ oncotarget.5420.

29. Kubeš J, Vondráček V, Andrlík M et al. Pencil‐beam scanning proton therapy for the treatment of glomus jugulare tumours. J Med Radiat Sci 2022; 69 (4) : 456–462. Doi: 10.1002/jmrs.612.